Acasti Pharma Inc. (ACST)

NASDAQ: ACST · IEX Real-Time Price · USD
3.330
-0.010 (-0.30%)
At close: Feb 27, 2024, 3:43 PM
3.300
-0.030 (-0.90%)
After-hours: Feb 27, 2024, 5:07 PM EST
-0.30%
Market Cap 31.68M
Revenue (ttm) n/a
Net Income (ttm) -38.77M
Shares Out 9.40M
EPS (ttm) -3.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 11,681
Open 3.300
Previous Close 3.340
Day's Range 3.300 - 3.400
52-Week Range 1.720 - 3.840
Beta 1.42
Analysts Strong Buy
Price Target 6.00 (+80.18%)
Earnings Date Feb 12, 2024

About ACST

Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Prashant Kohli
Employees 32
Stock Exchange NASDAQ
Ticker Symbol ACST
Full Company Profile

Financial Performance

Financial numbers in CAD Financial Statements

Analyst Forecast

According to one analyst, the rating for ACST stock is "Strong Buy" and the 12-month stock price forecast is $6.0.

Price Target
$6.0
(80.18% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights

PRINCETON, N.J., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine tha...

15 days ago - GlobeNewsWire

Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial

Accepted for Presentation at the 2024 International Stroke Conference Accepted for Presentation at the 2024 International Stroke Conference

26 days ago - GlobeNewsWire

Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024

PRINCETON, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel intravenous formulation of ni...

2 months ago - GlobeNewsWire

Acasti Announces Second Quarter 2024 Financial Results and Business Highlights

PRINCETON, N.J., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine tha...

3 months ago - GlobeNewsWire

Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial

PRINCETON, N.J., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine tha...

4 months ago - GlobeNewsWire

Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)

PRINCETON, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine tha...

5 months ago - GlobeNewsWire

Acasti Announces $7.5 Million Private Placement Equity Financing

PRINCETON, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine th...

5 months ago - GlobeNewsWire

Acasti to Participate in the H.C. Wainwright Global Investment Conference

PRINCETON, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine th...

6 months ago - GlobeNewsWire

Acasti Announces First Quarter 2024 Financial Results and Business Highlights

PRINCETON, N.J, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that...

7 months ago - GlobeNewsWire

Acasti to Present GTX-104 Pharmacokinetic Comparison Data at Neurocritical Care Annual Meeting

PRINCETON, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) ("Acasti" or the "Company"), a late-stage, biopharma company advancing GTX-104 its novel formulation of nimodipine ...

7 months ago - GlobeNewsWire

Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients

STRIVE-ON is a pivotal Phase 3 trial of GTX-104 to evaluate its comparable safety and tolerability profile relative to oral nimodipine in patients hospitalized with aSAH LAVAL, QB, July 10, 2023 /PRNe...

8 months ago - PRNewsWire

Acasti Pharma Announces 1-for-6 Reverse Stock Split

LAVAL, QB, July 7, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addre...

8 months ago - PRNewsWire

Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023

STRIVE-ON is the pivotal Phase 3 trial of GTX-104 to evaluate its comparable safety and tolerability profile relative to oral nimodipine in patients hospitalized with aSAH GTX-104 has been administere...

8 months ago - PRNewsWire

Acasti Pharma Reports Fiscal Year 2023 Operational Results

LAVAL, Québec, June 23, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that ...

8 months ago - PRNewsWire

Acasti Announces Appointment of New Scientific Advisory Board Members

LAVAL, QC , June 22, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that add...

8 months ago - PRNewsWire

Acasti to Participate in the Lytham Partners Spring 2023 Investor Conference

LAVAL, QC , May 17, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addr...

10 months ago - PRNewsWire

Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025

Company successfully submits GTX-104 Pivotal Phase 3 protocol IND amendment to the FDA with expectation for first patient dosed in calendar Q4 2023 Strategic realignment prioritizes GTX-104 and expect...

10 months ago - PRNewsWire

Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND

Company expects the first patient to be enrolled during the second half of 2023 LAVAL, QC , April 4, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, s...

11 months ago - PRNewsWire

Acasti Announces Appointment of Prashant Kohli as CEO

LAVAL, QC , April 4, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage specialty pharma company advancing drug candidates for rare and orphan diseases, t...

11 months ago - PRNewsWire

Acasti Pharma Inc. Announces the Resignation of a Director

LAVAL, QC , March 30, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST) a late-stage, specialty pharma company advancing three clinical stage drug candidates addressin...

11 months ago - PRNewsWire

Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange

Acasti also confirms no exposure to Silicon Valley Bank ("SVB") or Silvergate Bank LAVAL, Québec, March 13, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST and TSX-V:...

1 year ago - PRNewsWire

Acasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare Conference

LAVAL, QC, March 8, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candi...

1 year ago - PRNewsWire

Acasti Pharma Recognizes Rare Disease Day

LAVAL, QC , Feb. 28, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug cand...

1 year ago - PRNewsWire

Acasti Pharma Reports Third Quarter 2023 Operational Results

Company to Host Conference Call Today at 1:00pm ET

1 year ago - GlobeNewsWire

Acasti Pharma to Report Third Quarter 2023 Financial Results on Tuesday, February 14, 2023

Call to be held on Tuesday, February 14th at 1:00 PM Eastern Time LAVAL, QB, Feb. 7, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST and TSX-V: ACST), a late-stage, s...

1 year ago - PRNewsWire